It seems increasingly likely that President Obama’s last Food and Drug Administration commissioner, Robert Califf, will be going to work for Google biotech spinoff Verily Life Sciences.

Califf let slip in a talk to health care journalists earlier this month that he was considering joining Google, but did not elaborate. Then CNBC reported Tuesday, citing sources “familiar with the matter,” that Califf is talking with Verily about a leadership role. The job could still fall through, but would apparently involve a joint position at the Alphabet subsidiary and nearby Stanford University.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • call me biased, but I would say, it is all about having an illustrious insider knowledge on how to lobby and game the system.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy